Click on ‘Explanation about the score’ sign next to each entry to expand and learn more.
The company should publicly commit to human rights in relation to product development and marketing, by adopting an official human rights policy statement recognising the right to the highest attainable standard of health. The company should endeavour to integrate human rights into its strategies, policies, programmes, projects, and activities.
The company should also have a publicly available global access plan for their Covid-19 product, based on human rights standards, with measurable targets and lines of accountability.
Zydus Cadila has made an alliance with Enzychem, through which its vaccine will be supplied to low- and middle-income countries in Latin America and Asian New Southern Policy member countries.
Zydus Cadila has a human rights policy. It does not mention the UN Guiding Principles on Business and Human Rights or other internationally recognised human rights documents.
The company should constructively engage with international initiatives for the equitable distribution of vaccines and therapeutics, such as the Covid-19 Technology Access Pool (C-TAP) or the Medicines Patent Pool (MPP), and the ACT Accelerator (COVAX). The company should also publicly commit to not enforcing the exclusive rights of Covid-19 related patents, and enter into non-exclusive, transparent licensing agreements for its Covid-19 products with other companies.
Zydus Cadila has not committed to C-TAP or the MPP.
There is no evidence of Zydus Cadila not enforcing patents.
ZyCovD has not received WHO Emergency Use Listing, so it cannot yet participate in Covax
Zydus Cadila has licensed its vaccine to South Korea’s Enzychem Life Sciences to make at least 80 million doses (Cadila will receive license fees and royalty payments)
The company should engage in efforts to further equitable distribution of Covid-19 vaccines/therapeutics, by equitably distributing its supplies globally, devising fair pricing strategies, and making the active ingredient for its product available to other manufacturers. The company should also engage in full technology transfer to other manufacturers, including the necessary transfer of skills, legal components, knowledge and intellectual property. Where applicable, the company should agree to waive rights in regulatory test data, and refrain from enforcing TRIPS+ measures.
[Only applies to therapeutics]
The company is looking into it and backs the necessity of tech transfer. Zydus Cadila is in talks with other Indian manufacturers about technology transfer, and has already transferred the vaccine technology to South Korea’s Enzychem Life Sciences in exchange for license fees and royalty payments